We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Neutrophil Activation Underlies Cancer Drug's Antibacterial Effect

By LabMedica International staff writers
Posted on 28 Oct 2015
Print article
Image: Neutrophils produce bacteria-ensnaring NETs (shown in blue/green) in response to tamoxifen treatment (Photo courtesy of the University of California, San Diego).
Image: Neutrophils produce bacteria-ensnaring NETs (shown in blue/green) in response to tamoxifen treatment (Photo courtesy of the University of California, San Diego).
The bactericidal properties of the cancer drug tamoxifen have been linked to its modulation of sphingolipid biosynthesis and the effect this has on neutrophil activation and the generation of antimicrobial neutrophil extracellular traps (NETs).

Sphingosine (2-amino-4-octadecene-1,3-diol) is an 18-carbon amino alcohol with an unsaturated hydrocarbon chain, which forms a primary part of sphingolipids, a class of cell membrane lipids that include sphingomyelin, an important phospholipid.
Sphingosine can be phosphorylated in vivo via two kinases, sphingosine kinase type 1 and sphingosine kinase type 2. Phosphorylation leads to the formation of sphingosine-1-phosphate, a potent signaling lipid. Sphingolipid metabolites, such as ceramide, sphingosine, and sphingosine-1-phosphate, are lipid signaling molecules involved in diverse cellular processes.

In addition to its anti-cancer activity as an estrogen receptor agonist/antagonist, tamoxifen also modulates sphingolipid biosynthesis, which has been shown to play an important role in the regulation of neutrophil activity. To examine the importance of this role, investigators at the University of California, San Diego (USA) treated cultures of human neutrophils with tamoxifen.

Results published in the October 13, 2015, online edition of the journal Nature Communications revealed that compared to untreated neutrophils, tamoxifen-treated neutrophils were better at moving toward and phagocytosing bacteria. Tamoxifen-treated neutrophils also produced approximately three-fold more neutrophil extracellular traps (NETs),

NETs provide for a high local concentration of antimicrobial components and bind, disarm, and kill microbes extracellularly and independent of phagocytic uptake. In addition to their antimicrobial properties, NETs may serve as a physical barrier that prevents further spread of the pathogens. Furthermore, delivering the granule proteins into NETs may keep potentially injurious proteins like proteases from diffusing away and inducing damage in tissue adjacent to the site of inflammation.

In follow-up experiments the investigators treated MRSA (methicillin-resistant Staphylococcus aureus)-infected mice with tamoxifen. The drug significantly protected the mice: control mice survived less than one day after infection, while about 35% of the tamoxifen-treated mice survived five days. In addition, approximately five times fewer MRSA organisms were collected from the peritoneal fluid of the tamoxifen-treated mice, as compared to control mice.

“The threat of multidrug-resistant bacterial pathogens is growing, yet the pipeline of new antibiotics is drying up. We need to open the medicine cabinet and take a closer look at the potential infection-fighting properties of other drugs that we already know are safe for patients,” said senior author Dr. Victor Nizet, professor of pediatrics and pharmacy at the University of California, San Diego. “Through this approach, we discovered that tamoxifen has pharmacological properties that could aid the immune system in cases where a patient is immunocompromised or where traditional antibiotics have otherwise failed.”

“While known for its efficacy against breast cancer cells, many other cell types are also exposed to tamoxifen. The "off-target effects" we identified in this study could have critical clinical implications given the large number of patients who take tamoxifen, often every day for years,” said Dr. Nizet.

Related Links:

University of California, San Diego


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.